Dec'04 | Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow | $460.0M | $667.1M | $1,112.9M | $1,686.8M | $2,089.7M | $2,850.0M | $2,772.0M | $3,507.1M | $2,797.7M | $2,914.2M | $12.3B | $19.6B | $15.9B | $11.3B | $7,476.0M | $8,319.0M | $7,518.0M | $10.8B | $8,344.0M | $7,421.0M |
Discover the top 20 best undervalued stocks to buy for Jan 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued large-cap growth stocks to buy for Jan 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Jan 2025.
As of today, Gilead Sciences, Inc.'s last 12-month Free Cash Flow is $9,431.0M, based on the financial report for Sep 30, 2024 (Q3 2024).
Over the last year, Gilead Sciences, Inc.'s Free Cash Flow growth was 20.1%. The average annual Free Cash Flow growth rates for Gilead Sciences, Inc. have been 2.7% over the past three years, 3.2% over the past five years.
Over the last year, Gilead Sciences, Inc.'s Free Cash Flow growth was 20.1%, which is higher than industry growth of (0.2%). It indicates that Gilead Sciences, Inc.'s Free Cash Flow growth is Good.